नई दिल्ली: देश में कोरोना संक्रमण की दूसरी लहर का कहर जारी है. अभी भी रोज़ सवा लाख से अधिक नए केस दर्ज किए जा रहे हैं. स्वास्थ्य मंत्रालय के . | News Track
New Delhi: The United Arab Emirates (UAE) has banned entry of passengers from India till June 14. The UAE had banned entry of Indian passengers from April 25 following the second wave of the Covid-19 epidemic. Dubai s Airlines Emirates said in a statement that passenger flights from India have been cancelled till June 14, 2021. Passengers passing through India in the last 14 days will not be accepted to enter the United Arab Emirates (UAE) from any other point.
However, citizens of UAE, UAE golden visa holders and members of diplomatic missions who follow the revised Corona Protocol will be given concessions. Flights between the two countries will continue to allow transfer of exempted groups from India to UAE applying for transportation and discounts of passengers in India from UAE. The citizens of UAE, on diplomatic missions recognized by both countries, including official delegations, those travelling by commercial aircraft and golden visa holders, will be accepted as a precautio
Vials of the Sputnik V vaccine. | AFP
India on Thursday registered 3,62,727 new coronavirus cases, taking the infection tally to 2,37,03,665 since the pandemic broke out in January last year. The country’s toll rose to 2,58,317 as it reported 4,120 deaths in the last day.
The Union health ministry on Thursday said Covid-19 vaccine Sputnik V will be available in Indian markets from next week. This is the third Covid-19 vaccine to receive emergency-use authorisation in India. Over 200 crore vaccine shots are likely to be available by December, NITI Aayog member Dr VK Paul said.
The gap between two doses of the Covishield vaccine can be increased to 12-16 weeks, the Centre said on Thursday. Currently, the recommended gap is six to eight weeks. However, no changes were made to the dosage regimen of Covaxin, whose recommended gap period is four to six weeks. Meanwhile, Bharat Biotech got approval for clinical trials of Covaxin on children aged 2-18.